IndiaBreaking NewsBreakingLatest News
18 Patent Filings for Lenacapavir Raise Concerns Over HIV Drug Access
Sentiment: NegativeHigh Priority
What Happened?
Eighteen patent applications for lenacapavir in India may delay affordable generics and keep prices high, prompting opposition from patient groups. The drug is essential for HIV prevention and treatment.
Key points
- Eighteen patent applications for lenacapavir have been filed in India.
- Patient groups argue these patents lack novelty and may extend market exclusivity.
- Lenacapavir is a long-acting injectable for HIV prevention and treatment.
- The drug was approved by the US FDA as the first twice-yearly injectable pre-exposure prophylaxis.
- Gilead Sciences has filed patents covering various aspects of lenacapavir.
- If granted, patents could expire in 2042, legitimizing Gilead's evergreening strategy.
Key insights
- If patents are granted, it may lead to prolonged monopoly control over lenacapavir.
- The situation highlights ongoing challenges in balancing innovation and access to essential medicines.
- Patient groups may increase advocacy efforts to challenge the patent filings.
Why it matters
The patent filings could limit access to affordable HIV treatment for patients in India.
Entities
lenacapavir· ProductGilead Sciences· CompanyIndia· CountryWHO· Organization
Source
Times of India
